Fluvastatin

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heterozygous Familial Hypercholesterolemia

Conditions

Heterozygous Familial Hypercholesterolemia, Mixed Dyslipidemia

Trial Timeline

Oct 1, 2001 → Mar 1, 2005

NCT ID

NCT00171236

About Fluvastatin

Fluvastatin is a phase 3 stage product being developed by Novartis for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00171236. Target conditions include Heterozygous Familial Hypercholesterolemia, Mixed Dyslipidemia.

What happened to similar drugs?

1 of 14 similar drugs in Heterozygous Familial Hypercholesterolemia were approved

Approved (1) Terminated (1) Active (13)

✅PraluentSanofiApproved

🔄AZD0780 + PlaceboAstraZenecaPhase 3

🔄Anacetrapib + Placebo for anacetrapibMerckPhase 3

🔄InclisiranNovartisPhase 3

🔄Inclisiran + PlaceboNovartisPhase 3

🔄Evolocumab + PlaceboAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01045512	Phase 2	Terminated	Oct 1, 2009	Sep 1, 2014	Aging
NCT00136799	Phase 3	Completed	Jun 1, 2005	Apr 1, 2006	Mixed Dyslipidemia
NCT00125125	Approved	Completed	May 1, 2005	Dec 1, 2005	Dyslipidemia
NCT00138528	Approved	Completed	Oct 1, 2004	Feb 1, 2006	Metabolic Syndrome
NCT00171262	Approved	Completed	Aug 1, 2004	Jun 1, 2007	Dyslipidemia
NCT00171275	Approved	Completed	Nov 1, 2003	—	Coronary Disease
NCT00176410	Phase 2	UNKNOWN	Jan 1, 2003	Dec 1, 2009	Aortic Valve Stenosis
NCT00171236	Phase 3	Completed	Oct 1, 2001	Mar 1, 2005	Heterozygous Familial Hypercholesterolemia
NCT00565474	Approved	Completed	Sep 1, 2001	—	Graft Vasculopathy

Competing Products

18 competing products in Heterozygous Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Inclisiran + Placebo	Novartis	Phase 3	47
Evolocumab + Placebo	Amgen	Phase 3	40
Bococizumab (PF-04950615;RN316)	Pfizer	Phase 3	40
Atorvastatin + Atorvastatin	Pfizer	Phase 1	29
IBI306 + placebo	Innovent Biologics	Phase 3	40
Lumacaftor Plus Ivacaftor Combination + Ivacaftor	Vertex Pharmaceuticals	Phase 3	40
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo	Sanofi	Phase 3	40
Placebo + Alirocumab	Sanofi	Phase 3	40
Praluent	Sanofi	Approved	35
AK102 + Placebo + Statins and/or Ezetimibe	Akeso	Phase 2	35
lerodalcibep	Medpace	Phase 3	37
mipomersen sodium + placebo	Ionis Pharmaceuticals	Phase 3	37
MGL-3196 (resmetirom) + Placebo	Madrigal Pharmaceuticals	Phase 2	32